Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) FCF Margin: 2019-2025

Historic FCF Margin for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to 18.49%.

  • Legend Biotech's FCF Margin rose 5501.00% to 18.49% in Q3 2025 from the same period last year, while for Sep 2025 it was -23.66%, marking a year-over-year increase of 1247.00%. This contributed to the annual value of -30.63% for FY2024, which is 13053.00% up from last year.
  • Per Legend Biotech's latest filing, its FCF Margin stood at 18.49% for Q3 2025, which was up 236.31% from -13.57% recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's FCF Margin peaked at 18.49% during Q3 2025, and registered a low of -120,930.23% during Q4 2023.
  • For the 3-year period, Legend Biotech's FCF Margin averaged around -15,073.88%, with its median value being -47.13% (2023).
  • In the last 5 years, Legend Biotech's FCF Margin crashed by 12,074,692bps in 2023 and then soared by 7,672,526bps in 2024.
  • Quarterly analysis of 5 years shows Legend Biotech's FCF Margin stood at -183.91% in 2021, then surged by 59bps to -183.32% in 2022, then tumbled by 12,074,692bps to -120,930.23% in 2023, then soared by 7,672,526bps to -44,204.97% in 2024, then soared by 5,501bps to 18.49% in 2025.
  • Its last three reported values are 18.49% in Q3 2025, -13.57% for Q2 2025, and -53.47% during Q1 2025.